MedTrace Logo

Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors

NCT06872489 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-07-23

No results posted yet for this study

Summary

This is an Expanded Access Program (EAP) that will give the participants access to the drug SL-28 before it is approved by the FDA. Participants in this study will have Advanced Solid Tumors who failed to respond to standard therapy (chemotherapy, immunotherapy) or developed progressive disease at any phase of standard therapy.

Researchers think the SL-28 will be effective because SL-28 has a direct activity against different types of tumors.

SL-28 is a cell-based therapy, based on leukocytes isolated from healthy donors and are activated through the proprietary process. After quality assessment (sterility, viable cell count, purity, and absence of infectious diseases), they are stored at -80°C until use. Upon need, the SL-28 is thawed, followed by checking their viability, count, and sterility. Adult and older adult patients aged 18 to 65+ who meet the eligibility criteria will be included in the study. Patients receive SL-28 IV once daily on days 1-5 and 8-12. Based on the patient's response, the need for additional injections will be evaluated. If improvements in the patient's condition are confirmed by MRI, further injections can continue on a rate 5 days a week.

Conditions

Interventions

BIOLOGICAL

SL-28.

Allogeneic, non-HLA matched, Leucocyte-Tells-based therapy

Sponsors & Collaborators

  • Second Life Therapeutics

    lead INDUSTRY

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06872489 on ClinicalTrials.gov